T-65

未知生产厂商

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

ANTI-CD40 ANTIBODY, ANTI-PD-L1×CD40 BISPECIFIC ANTIBODY, AND USE THEREOF
EP 4534559 A4申请人: FUTUREGEN BIOPHARMACEUTICAL BEIJING CO LTD优先权: 2022
CN
EP
US
WO
4 件公开
Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
EP 2103689 A1申请人: GENTIUM SPA优先权: 2008
CN
EP
US
4 件公开
Methods of using antibodies to human receptor protein 4-1BB
US 6905685 B2申请人: KWON BYOUNG S优先权: 2000
US
4 件公开
Nucleic acid molecules encoding human 4-1BB
US 8026353 B2申请人: UNIV INDIANA RES & TECH CORP优先权: 2001
US
4 件公开
Peptidomimetics that mimic a conformational-dependent neutralizing epitope of the human immunodeficiency virus (HIV) CCR5 coreceptor
US 7700273 B2申请人: US HEALTH优先权: 2005
US
4 件公开
CELL PENETRATING POLYPEPTIDES (CPPS) AND THEIR USE IN HUMAN THERAPY
- EP 4448556 A1
  申请人: RDP PHARMA AG优先权: 2021
  EP
  US
  WO
  3 件公开
- CN 118786136 A
  申请人: RDP PHARMA AG优先权: 2022
  CN
BIO-CONJUGATES FOR ONCOLOGY
EP 4480497 A1申请人: RDP PHARMA AG优先权: 2023
EP
WO
3 件公开
STAT3 EPITOPE PEPTIDES
US 2011052614 A1申请人: ONCOTHERAPY SCIENCE INC优先权: 2008
CN
US
2 件公开
PLASMID CONTAINING A SEQUENCE ENCODING AN MRNA WITH A SEGMENTED POLY(A) TAIL
EP 4306643 A2申请人: ETHRIS GMBH优先权: 2018
CN
EP
2 件公开
METHOD FOR AMPLIFYING IN-VITRO INDUCED CD4 +FOXP3 +CD69 +TREG AND USE THEREOF
WO 2022022599 A1申请人: UNIV ZHEJIANG优先权: 2020
CN
WO
2 件公开